share_log

Merit Medical Launches the Micro ACE Advanced Micro-Access System

Merit Medical Launches the Micro ACE Advanced Micro-Access System

Merit Medical 推出 Micro ACE 高级微接入系统
GlobeNewswire ·  03/19 09:25

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases

Micro ACE 结合了刚度和弹性的独特平衡,可在具有挑战性的案例中成功实现微接入

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. Merit also intends to file Micro ACE for CE mark designation.

犹他州南乔丹,2024年3月19日(GLOBE NEWSWIRE)——医疗保健技术的全球领导者Merit Medical Systems, Inc.(纳斯达克股票代码:MMSI)今天宣布其经美国食品药品监督管理局(FDA)批准的Micro ACE高级微访问系统的商业发布。Merit 还打算向 Micro ACE 申请 CE 标志认证。

The Micro ACE system is the latest innovation in the Merit Vascular portfolio. The comprehensive portfolio includes a full range of percutaneous access and closure devices. Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.

Micro ACE 系统是 Merit Vascular 产品组合中的最新创新。全面的产品组合包括全系列的经皮穿刺和封闭设备。Micro ACE 结合了刚度和弹性的平衡,旨在实现各种血管解剖结构的微接入。

Interventional procedures utilizing micro-access are commonly performed to diagnose and open narrowed (i.e., atherosclerotic) blood vessels. Atherosclerosis is an inflammatory condition that develops when there is a buildup of plaque inside the arteries. Diseases linked to atherosclerosis, such as coronary and peripheral artery disease, are the leading cause of death in the United States.1

使用微通道的介入手术通常用于诊断和打开狭窄(即动脉粥样硬化)的血管。动脉粥样硬化是一种炎症性疾病,当动脉内有斑块积聚时就会发生。与动脉粥样硬化相关的疾病,例如冠状动脉和外周动脉疾病,是美国的主要死因。1

To facilitate such interventional procedures, the Micro ACE balances stiffness and flexibility to offer twice the resistance to kink and compression over the leading competitor. 2 It is also 9% stiffer than the leading standard micro-introducer. 2 In addition, a unique marker tip design allows for nine times greater visibility under fluoroscopy for accurate positioning needed at the start of a procedure.2 Merit is pursuing patents on Micro ACE technology in the United States and internationally.

为了便于进行此类介入手术,Micro ACE 平衡了刚度和灵活性,其抗扭结和压缩能力是主要竞争对手的两倍。 2 它的硬度也比领先的标准微型导入器高9%。 2 此外,独特的标记笔尖设计可在透视镜下将能见度提高九倍,从而在手术开始时实现所需的精确定位。2 Merit 正在美国和国际上申请微型 ACE 技术的专利。

Learn more about the Micro ACE.

了解有关 Micro ACE 的更多信息。

"Merit has always looked for opportunities to improve patient care. Micro ACE leverages our experience with reinforced sheath design to improve a procedure that is done over and over each day," said Fred P. Lampropoulos, Merit's Chairman and CEO. "We are excited to partner with interventional physicians to advance vascular access."

“Merit 一直在寻找改善患者护理的机会。Micro ACE利用我们在加固护套设计方面的经验来改进每天反复进行的手术。” Merit董事长兼首席执行官弗雷德·兰普罗普洛斯说。“我们很高兴能与介入医生合作推进血管通路。”

ABOUT MERIT MEDICAL

关于美德医疗

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,000 people worldwide.

Merit Medical Systems, Inc. 成立于1987年,从事专有的一次性医疗器械的开发、制造和分销,用于介入、诊断和治疗程序,尤其是心脏病学、放射学、肿瘤学、重症监护和内窥镜检查。Merit 拥有一支总计 700 多人的国内和国际销售队伍和临床支持团队,为全球客户医院提供服务。Merit 在全球拥有大约 7,000 名员工。

TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

商标
除非另有说明,否则本新闻稿中使用的商标和注册商标均为Merit Medical Systems, Inc.、其子公司或其许可方的财产。

CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com

联系人
公关/媒体查询
莎拉·康斯托克
美瑞医疗
+1-801-432-2864 | sarah.comstock@merit.com

INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com

投资者查询
迈克·皮奇尼诺,特许金融分析师,IRC
韦斯特威克-ICR
+1-443-213-0509 | mike.piccinino@westwicke.com

1. National Heart, Lung, and Blood Institute (NIH). 2022. "Atherosclerosis." Last modified March 24, 2022. Accessed March 18, 2024.

1。国家心肺血液研究所(NIH)。2022年。“动脉粥样硬化。”上次修改时间为2022年3月24日。于 2024 年 3 月 18 日访问。

2. Data on File.

2。文件中的数据。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发